AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD

AsclepiX Therapeutics
AsclepiX Therapeutics, Inc. Strengthens Board of Directors, Welcomes Steven Altschuler, MD

• AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides for cancer, adds Steven Altschuler, MD to Board of Directors.
• Dr. Altschuler, the founder and Chairman of the Board of Spark Therapeutics Inc. (NASDAQ: ONCE), brings to AsclepiX a deep knowledge and experience in developing novel therapies for the treatment of retinal disease.